Attention Deficit Disorder With Hyperactivity (ADHD)HITADHDNCT07675538
High Intensity Training for Adults With ADHD in Specialised Mental Health Care
A study testing High intensity training in people with Attention Deficit Disorder With Hyperactivity (ADHD), run by Solli Distriktspsykiatriske Senter at 1 site in Norway.
Trial summary
Attention-Deficit/Hyperactivity Disorder (ADHD) is a lifelong neurodevelopmental disorder characterised by persistent symptoms of inattention, hyperactivity, and impulsivity. According to the DSM-5, these symptoms must be present for at least six months, have an onset in childhood, and result in significant impairment… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Attention Deficit Disorder With Hyperactivity (ADHD)
- What is being tested?
- High intensity training
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteNorway
- Study dates
- 1 Feb 2026to 30 Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Above 18 years
- An ADHD diagnosis (F90.0 in the ICD-10)
Who cannot join
- Psychiatric conditions not compatible with participation incl. ongoing psychotic episode, mania, acute suicidality etc.,
- Physical conditions precluding participation in physical testing and/or exercise
- Comprehensive ongoing substance use determined by the Alcohol Use Disorders IdentificationTest (AUDIT; Babor et al., 2001) and the Drug Use Disorder Identification Test (DUDIT; Berman et al., 2003). An AUDIT cut-off score of 16 (high risk), and/or DUDIT score of 20 (high risk) will lead to screening with MINI International Neuropsychiatric Interview (Lecrubier etal., 1997; Sheehan et al., 1998).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: High-intensity Training for Adults With ADHD in Specialised Mental Health Care: A Mixed Methods Feasibility Study
Attention-Deficit/Hyperactivity Disorder (ADHD) is a lifelong neurodevelopmental disorder characterised by persistent symptoms of inattention, hyperactivity, and impulsivity. According to the DSM-5, these symptoms must be present for at least six months, have an onset in childhood, and result in significant impairment in multiple life domains. Although ADHD may be limited to childhood in some cases, most individuals continue to have symptoms and impairments in varying degrees in adult life. The prevalence of persistent ADHD among adults is estimated to be approximately 2.58%, depending on diagnostic criteria and sample selection. The increasing awareness of ADHD has led to a marked increase in referrals to mental health services, which places greater demands on the development of effective and accessible treatment options for this group.
Pharmacological treatment, particularly the use of stimulants, is a common intervention for adults with ADHD and has been shown to be effective for many. However, there are also side effects associated with drug treatment, and there is a need for more evidence-based non-drug alternatives. In addition, discontinuation of medication is common in ADHD treatment. Psychological interventions include psychoeducation and cognitive behaviour therapy, as well as more specialised approaches based on Dialectical Behaviour Therapy and Goal Management Training, which aim to improve executive functions. Whilst pharmacotherapy and psychotherapeutic interventions help some people with ADHD, not all people experience favourable outcomes, which calls for alternative treatment approaches. Interventions targeting the core symptoms of ADHD, executive functions, and behaviour are particularly relevant to treatment provision.
Read more
One approach to improving executive functioning that has received increasing attention is physical exercise. Studies have shown that physical activity can have a positive effect on cognitive function, executive control, and behaviour in children and adolescents with ADHD. Physical exercise may also be applied as treatment for comorbid factors common in ADHD, such as mood disorders and multiple long-term physical conditions. Despite increasing interest in physical activity as a treatment modality, research on physical exercise for adults with ADHD is still limited. The findings from studies on younger age groups point to the potential for similar effects in adults, but more research is needed to examine the effects of physical exercise as a targeted intervention in the adult population with ADHD.
Among the different types of physical activity, high-intensity interval training (HIIT) has gained promise for mental health. Due to its rapid, alternating, and fast-paced style, it could prove useful for those with ADHD. However, research on high-intensity interval training interventions (HIIT) in this population is scarce. To address these unanswered questions, this project will conduct a feasibility trial for a randomised controlled trial (RCT) to assess the feasibility and acceptability of HIIT among people with ADHD.
- Being tested
- High intensity training
- Keywords
- ADHD, Physical exercise, High intensity training
- Medical subject headings
- Attention Deficit Disorder with Hyperactivity, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
High intensity trainingBehavioural
14 weeks of high intensity training of strenght and endurace.
| Study group | Role | What they receive |
|---|---|---|
| High intensity training | Experimental | Fourteen weeks of high intensity strenght and endurance training after a protocol. Receives: Behavioral: High intensity training |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility of the intervention: Recruitment rate
Recruitment rate: Proportion of eligible participants who agree to participate in the study ((Number of participants recruited/Number of eligible participants) x 100). Aim: >50%.
Measured: through study completion, an average of 1 year
Feasibility measure: Retention rate
Retention rate: Proportion of participants who remain in the study until completion ((Number of participants completing the study/Number of participants enrolled) x 100). Aim: >80%.
Measured: through study completion, an average of 1 year
Feasibility measure: Dropout rate
Dropout rate: How many participants dropped out after inclusion. Registration of reasons of dropout.
Measured: through study completion, an average of 1 year
Feasibility measure: Compliance
Compliance: How many sessions each participant attended. Registration of reasons of sessions not attended.
Measured: through study completion, an average of 1 year
Feasibility measure: Adherence to protocol
Adherence to protocol: How many elements in the physical exercise program were conducted in each session. Physical exercise diary for registration of load and intensity of strength- and endurance training, respectively. Aim: >80%. Also, registration of adherence to the total test protocol.
Measured: through study completion, an average of 1 year
Secondary outcomes (17)
In depth interview
Participants will be invited to an in-depth interview lasting approx. 45 minutes, after the treatment intervention. The aim is to explore experiences with physical exercise in relation to core symptoms of ADHD. A semi-structured interview protocol with open questions and additional probes is used to promote exploratory dialogue on the participants experience with participation. All interviews will be audio recorded and transcribed verbatim. By comparing the individual accounts, we want to identify both patterns of commonalities and differences in participants' experiences, providing important descriptions of patient experiences that may contribute to detect challenges with the intervention that can be utilised for further development and implementation.
Measured: Participants are inviteted within two weeks after ending their participation
General Ability - WAIS-IV
Six sub tests from the general ability test Wecshler Adult Intelligence Scale will be used to assess General Ability Index, Verbal Comprehension Index and Perceptual Reasoning Index.
The six subtests are: Block Design, Similarities, Matrix Reasoning, Vocabulary, Digit Span and Coding.
Measured: Within two weeks before initating intervention.
The Adult ADHD Self-Report Scale
The Adult ADHD Self-Report Scale (ASRS) is a patient-reported outcome measure assessing the frequency and severity of adult ADHD symptoms. Items are rated on a 5-point Likert scale (0-4), with higher total scores reflecting greater ADHD symptom severity. Lower scores reflect fewer self-reported ADHD symptoms.
Measured: Within two weeks before initating intervention. Within two weeks after ending intervention.
The Working Memory Questionnaire
The Working Memory Questionnaire (WMQ) is a patient-reported outcome measure designed to assess everyday difficulties related to working memory functioning. It evaluates the frequency of memory-related problems experienced in daily life, including difficulties with remembering information, maintaining attention, following instructions, and managing cognitive tasks.
The WMQ consists of items rated on a Likert-type scale, where participants indicate how often they experience specific working memory difficulties. A total score is calculated by summing item responses. Higher scores indicate greater perceived working memory difficulties and a higher level of impairment in everyday cognitive functioning. Lower scores indicate fewer reported working memory problems and better perceived working memory functioning.
The total WMQ score is calculated by summing responses across items (with item scoring depen
Measured: Within two weeks before first intervention session and within two weeks after completion of the last session.
The Generalized Anxiety Disorder-7
The Generalized Anxiety Disorder-7 (GAD-7) is a patient-reported outcome measure assessing anxiety symptom severity. Items are scored from 0-3 based on symptom frequency over the previous two weeks, producing a total score from 0-21. Higher scores indicate greater anxiety symptom severity, while lower scores indicate fewer anxiety symptoms
Measured: Within two weeks before first intervention session and within two weeks after completion of the last session.
The Patient Health Questionnaire-9
The Patient Health Questionnaire-9 (PHQ-9) is a patient-reported outcome measure assessing depressive symptom severity. Items are scored from 0-3 based on symptom frequency over the previous two weeks, producing a total score from 0-27. Higher scores indicate greater depressive symptom severity, while lower scores indicate fewer depressive symptoms.
Measured: Within two weeks before first intervention session and within two weeks after completion of the last session.
The Bergen Insomnia Scale
The Bergen Insomnia Scale (BIS) is a patient-reported outcome measure assessing insomnia symptoms and sleep-related impairment. Six items are rated from 0-7 according to symptom frequency over the previous month, producing a total score from 0-42. Higher scores indicate greater insomnia symptom severity, while lower scores indicate fewer insomnia symptoms.
Measured: Within two weeks before first intervention session and within two weeks after completion of the last session.
The International Physical Activity Questionnaire
The International Physical Activity Questionnaire (IPAQ) is a patient-reported outcome measure assessing physical activity and sedentary behavior. It measures frequency and duration of walking, moderate-intensity, and vigorous-intensity activities over a specified recall period. Scores are calculated as MET-minutes/week, with higher scores indicating greater physical activity and lower scores indicating less physical activity.
Measured: Within two weeks before first intervention session and within two weeks after completion of the last session.
The Work and Social Adjustment Scale
The Work and Social Adjustment Scale (WSAS) is a patient-reported outcome measure assessing functional impairment associated with a health condition. Five items are rated from 0-8, producing a total score from 0-40. Higher scores indicate greater impairment in work, social, and daily functioning, while lower scores indicate better functioning.
Measured: Within two weeks before first intervention session and within two weeks after completion of the last session.
The Adult ADHD Quality of Life
The Adult ADHD Quality of Life (AAQoL) is a validated self-report questionnaire designed to assess health-related quality of life in adults with attention-deficit/hyperactivity disorder (ADHD). The instrument evaluates the impact of ADHD symptoms on daily functioning and well-being across multiple domains, including life productivity, psychological health, relationships, and outlook.
The AAQoL consists of 29 items, each rated on a Likert-type scale reflecting the frequency or severity of difficulties experienced over a specified recall period. Item responses are combined and transformed into domain scores and an overall total score.
Item responses are aggregated and converted to standardized scores ranging from 0 to 100 for the total scale and each domain. Higher scores indicate better health-related quality of life, while lower scores indicate poorer quality of life and greater ADHD-related f
Measured: Within two weeks before first intervention session and within two weeks after completion of the last session.
Credibility/Expectancy Questionnaire
The Credibility/Expectancy Questionnaire (CEQ) is a patient-reported measure assessing perceived treatment credibility and expectancy for improvement. It consists of 5 items where patients rate themselves on a likert scale from 0-10. It produces a total scores, with higher scores indicating greater perceived credibility and stronger expectations of treatment benefit.
Measured: Within two weeks before first intervention session and within two weeks after completion of the last session.
The Negative Effects Questionnaire - Short Form
The Negative Effects Questionnaire - Short Form (NEQ-S) is a patient-reported outcome measure assessing perceived negative or unwanted effects of an intervention. Higher scores indicate a greater number and/or severity of self-reported adverse effects.
Measured: Within two weeks after completion of the last session.
The Wechsler Memory Scale - Third Edition
The Wechsler Memory Scale - Third Edition (WMS-III) Spatial Memory subtest is a clinician-administered measure of visuospatial memory. Standardized age-adjusted scores are derived, with higher scores indicating better spatial memory performance and lower scores indicating poorer spatial memory.
Measured: Within two weeks before first intervention session and within two weeks after completion of the last session.
D-KEFS Trail Making Test
The D-KEFS Trail Making Test is a clinician-administered measure of executive function assessing visual scanning, processing speed, and cognitive flexibility. Performance is measured by time to completion and standardized scaled scores, with higher scores (and faster completion times) indicating better executive functioning."
Measured: Within two weeks before first intervention session and within two weeks after completion of the last session.
D-KEFS Color-Word Interference Test
The D-KEFS Color-Word Interference Test is a clinician-administered measure of executive function assessing response inhibition and cognitive flexibility. Performance is measured by time to completion and standardized scaled scores, with higher scores (and faster completion times) indicating better executive functioning.
Measured: Within two weeks before first intervention session and within two weeks after completion of the last session.
Maximal strenght
Maximal strength is assessed using the one-repetition maximum (1RM) test for lower-body and upper-body strength. In this study, maximal lower-body strength is assessed using a leg strength exercise (e.g., leg press or squat depending on protocol), and upper-body strength is assessed using the bench press.
The primary outcome is the maximal load lifted successfully for one repetition, recorded in kilograms (kg). Separate 1RM values are obtained for leg strength and bench press.
Higher scores: Indicate greater maximal muscular strength and neuromuscular performance in the tested muscle groups.
Lower score
Measured: Within two weeks before first intervention session and within two weeks after completion of the last session.
Maximal oxygen uptake
Maximal oxygen uptake (VO₂max) is an estimate of the maximum rate at which oxygen can be utilized during intense aerobic exercise and is a key indicator of cardiorespiratory fitness. In this study, VO₂max is estimated using the Myworkout GO mobile application (Helgerud et al., 2022), which derives VO₂max from performance data collected during a standardized treadmill-based interval protocol (4×4 endurance session).
The estimation is based on recorded treadmill speed and incline during the exercise session, which are used to model aerobic capacity according to validated predictive algorithms.
VO₂max is reported as an estimated continuous variable in milliliters of oxygen per kilogram of body weight per minute (mL·kg-¹·min-¹). Higher values indicate greater aerobic capacity and cardiorespiratory fitness, while lower values indicate reduced aerobic fitness.
Measured: Within two weeks before first intervention session and within two weeks after completion of the last session.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jun 2026
- Study start1 Feb 2026
- Primary completion1 Jun 2027 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Attention Deficit Disorder With Hyperactivity (ADHD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Solli Distriktspsykiatriske Senter
- Sponsor type
- University, hospital or other
- Collaborators
- Helse-Bergen HF
- Responsible party
- Sponsor
- Investigators
- Kristine Sirevåg, PhD, Principal investigator, Solli DPS
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07675538
- Sponsor's protocol ID
- 938442
- Acronym
- HITADHD
- Status last verified
- Jun 2026
- First submitted
- 15 Jan 2026
- Last updated
- 30 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: This has not been applied for to the ethical Committee.
Study at a glance
From the registry record, last updated by the sponsor on 30 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- High-intensity Training for Adults With ADHD in Specialised Mental Health Care: A Mixed Methods Feasibility Study
- ClinicalTrials.gov ID
- NCT07675538
- Acronym / sponsor ID
- HITADHD / 938442
- Keywords
- ADHD, Physical exercise, High intensity training
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Solli Distriktspsykiatriske SenterUniversity, hospital or other
- Collaborators
- Helse-Bergen HF
- Study start
- 1 Feb 2026 (actual)
- Primary completion
- 1 Jun 2027 (estimated)
- Study completion
- 30 Jun 2027 (estimated)
- First posted
- 30 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Attention-Deficit/Hyperactivity Disorder (ADHD) is a lifelong neurodevelopmental disorder characterised by persistent symptoms of inattention, hyperactivity, and impulsivity. According to the DSM-5, these symptoms must be present for at least six months, have an onset in childhood, and result in significant impairment in multiple life domains. Although ADHD may be limited to childhood in some cases, most individuals continue to have symptoms and impairments in varying degrees in adult life. The prevalence of persistent ADHD among adults is estimated to be approximately 2.58%, depending on diagnostic criteria and sample selection. The increasing awareness of ADHD has led to a marked increase in referrals to mental health services, which places greater demands on the development of effective and accessible treatment options for this group.
Pharmacological treatment, particularly the use of stimulants, is a common intervention for adults with ADHD and has been shown to be effective for many. However, there are also side effects associated with drug treatment, and there is a need for more evidence-based non-drug alternatives. In addition, discontinuation of medication is common in ADHD treatment. Psychological interventions include psychoeducation and cognitive behaviour therapy, as well as more specialised approaches based on Dialectical Behaviour Therapy and Goal Management Training, which aim to improve executive functions. Whilst pharmacotherapy and psychotherapeutic interventions help some people with ADHD, not all people experience favourable outcomes, which calls for alternative treatment approaches. Interventions targeting the core symptoms of ADHD, executive functions, and behaviour are particularly relevant to treatment provision.
One approach to improving executive functioning that has received increasing attention is physical exercise. Studies have shown that physical activity can have a positive effect on cognitive function, executive control, and behaviour in children and adolescents with ADHD. Physical exercise may also be applied as treatment for comorbid factors common in ADHD, such as mood disorders and multiple long-term physical conditions. Despite increasing interest in physical activity as a treatment modality, research on physical exercise for adults with ADHD is still limited. The findings from studies on younger age groups point to the potential for similar effects in adults, but more research is needed to examine the effects of physical exercise as a targeted intervention in the adult population with ADHD.
Among the different types of physical activity, high-intensity interval training (HIIT) has gained promise for mental health. Due to its rapid, alternating, and fast-paced style, it could prove useful for those with ADHD. However, research on high-intensity interval training interventions (HIIT) in this population is scarce. To address these unanswered questions, this project will conduct a feasibility trial for a randomised controlled trial (RCT) to assess the feasibility and acceptability of HIIT among people with ADHD.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| High intensity training | Experimental | Behavioral: High intensity trainingFourteen weeks of high intensity strenght and endurance training after a protocol. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Above 18 years
- An ADHD diagnosis (F90.0 in the ICD-10)
Key exclusion criteria (3 listed)
- Psychiatric conditions not compatible with participation incl. ongoing psychotic episode, mania, acute suicidality etc.,
- Physical conditions precluding participation in physical testing and/or exercise
- Comprehensive ongoing substance use determined by the Alcohol Use Disorders IdentificationTest (AUDIT; Babor et al., 2001) and the Drug Use Disorder Identification Test (DUDIT; Berman et al., 2003). An AUDIT cut-off score of 16 (high risk), and/or DUDIT score of 20 (high risk) will lead to screening with MINI International Neuropsychiatric Interview (Lecrubier etal., 1997; Sheehan et al., 1998).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| High intensity training14 weeks of high intensity training of strenght and endurace. | Behavioural | High intensity training |
Primary outcome
Feasibility of the intervention: Recruitment rate
Time frame: through study completion, an average of 1 year
Recruitment rate: Proportion of eligible participants who agree to participate in the study ((Number of participants recruited/Number of eligible participants) x 100). Aim: >50%.
Feasibility measure: Retention rate
Time frame: through study completion, an average of 1 year
Retention rate: Proportion of participants who remain in the study until completion ((Number of participants completing the study/Number of participants enrolled) x 100). Aim: >80%.
Feasibility measure: Dropout rate
Time frame: through study completion, an average of 1 year
Dropout rate: How many participants dropped out after inclusion. Registration of reasons of dropout.
Feasibility measure: Compliance
Time frame: through study completion, an average of 1 year
Compliance: How many sessions each participant attended. Registration of reasons of sessions not attended.
Feasibility measure: Adherence to protocol
Time frame: through study completion, an average of 1 year
Adherence to protocol: How many elements in the physical exercise program were conducted in each session. Physical exercise diary for registration of load and intensity of strength- and endurance training, respectively. Aim: >80%. Also, registration of adherence to the total test protocol.
17 secondary outcomes
In depth interview
Time frame: Participants are inviteted within two weeks after ending their participation
General Ability - WAIS-IV
Time frame: Within two weeks before initating intervention.
The Adult ADHD Self-Report Scale
Time frame: Within two weeks before initating intervention. Within two weeks after ending intervention.
The Working Memory Questionnaire
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
The Generalized Anxiety Disorder-7
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
The Patient Health Questionnaire-9
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
The Bergen Insomnia Scale
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
The International Physical Activity Questionnaire
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
The Work and Social Adjustment Scale
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
The Adult ADHD Quality of Life
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
Credibility/Expectancy Questionnaire
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
The Negative Effects Questionnaire - Short Form
Time frame: Within two weeks after completion of the last session.
The Wechsler Memory Scale - Third Edition
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
D-KEFS Trail Making Test
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
D-KEFS Color-Word Interference Test
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
Maximal strenght
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
Maximal oxygen uptake
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jun 2026.
- Individual participant dataSharing planned: No. This has not been applied for to the ethical Committee.
Related trials for Attention Deficit Disorder With Hyperactivity (ADHD)
Enrolling by invitationPhase 3
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD
ADHD
RecruitingObservational study
Augmenting Parent Management Training for Child Temper Outbursts Using a Digital Tool
Disruptive Behavior Disorders, Conduct Disorder
Recruiting
Micronutrient Supplementation and Chronotherapy in Children With ADHD
Attention Deficit Hyperactivity Disorder (ADHD)
RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
ADHD
RecruitingPhase 3
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Kristine Sirevåg, PhD principal investigator
Solli DPS
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing High intensity training in people with Attention Deficit Disorder With Hyperactivity (ADHD), run by Solli Distriktspsykiatriske Senter at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 30 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility of the intervention: Recruitment rate (time frame: through study completion, an average of 1 year). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jun 2026.